Review



cd8 t cell depletion experiment  (Bio X Cell)


Bioz Verified Symbol Bio X Cell is a verified supplier
Bioz Manufacturer Symbol Bio X Cell manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 96

    Structured Review

    Bio X Cell cd8 t cell depletion experiment
    Cd8 T Cell Depletion Experiment, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 96/100, based on 286 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cd8 t cell depletion experiment/product/Bio X Cell
    Average 96 stars, based on 286 article reviews
    cd8 t cell depletion experiment - by Bioz Stars, 2026-04
    96/100 stars

    Images



    Similar Products

    97
    Miltenyi Biotec cd8 t cell depletion
    Cd8 T Cell Depletion, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cd8 t cell depletion/product/Miltenyi Biotec
    Average 97 stars, based on 1 article reviews
    cd8 t cell depletion - by Bioz Stars, 2026-04
    97/100 stars
      Buy from Supplier

    96
    Bio X Cell cd8 t cell depletion experiment
    Cd8 T Cell Depletion Experiment, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cd8 t cell depletion experiment/product/Bio X Cell
    Average 96 stars, based on 1 article reviews
    cd8 t cell depletion experiment - by Bioz Stars, 2026-04
    96/100 stars
      Buy from Supplier

    95
    Selleck Chemicals cd8 t cells depletion
    A The expression of neutrophils and <t>CD8</t> + T cells in low- and high-glycolysis clusters, divided by ssGSEA score of glycolysis-related genes, in TCGA and CPTAC PAAD database. Data are presented as box plots showing the median (center line), the first and third quartiles (box bounds), and the whiskers extend to 1.5 times the interquartile range from the box. B The correlation of glycolysis level and neutrophils or CD8 + T cells expression in TCGA ( n = 179 patients) and CPTAC ( n = 140 patients) PAAD database. C Kaplan–Meier plots representing survival probabilities in TCGA-PAAD patients according to the relative level of glycolysis-related or neutrophil-related gene expression. D The diagram illustrating the targets of 2DG and shRNA in the glycolysis process. E CyTOF analysis of tumor-infiltrating immunocytes in subcutaneous tumor models with or without 2DG treatment: tSNE plots showing 12 meta-clusters based on the expression of 41 markers for the immunocytes. F Bar chart of the frequencies of the immune cell subsets in two experimental groups. G A schematic diagram showing the orthotopic PDAC model ( n = 6 mice per group in one experiment) with or without 2DG treatment. H , I Image and weights of the orthotopic tumors in the experimental groups from ( G ) at the end of the experiments. ( n = 6 mice per group). ( J – M ) Tumor-infiltrating neutrophils, CD8 + T cells, GZMB + CD8 + T cells, and PD-1 + CD8 + T cells isolated from the orthotopic tumors were analyzed using flow cytometry: representative graphs of flow cytometry (left panel) and statistical analysis of the cell ratio (right panel) ( n = 6 mice per group). N A schematic diagram showing the orthotopic tumor model in C57BL/6 J mice ( n = 6 mice per group in one experiment) treated with or without anti-Ly6G/anti-CD8 antibody. O , P Image and weights of the orthotopic tumors in the experimental groups from ( N ) at the end of the experiments ( n = 6 mice per group). Q – S Tumor-infiltrating neutrophils, CD8 + T cells, and GZMB + CD8 + T cells isolated from the orthotopic tumors were analyzed using flow cytometry: Representative graphs of flow cytometry (left panel) and statistical analysis of the cell ratio (right panel) ( n = 6 mice per group). T , U Representative luminescence images of the mouse model in ( N ) and statistical analysis of the total flux ( n = 6 mice per group). Data represent mean ± SEM. Statistical analysis was conducted using the two-tailed unpaired Student’s t test ( A, I–M, P–S, and U ), two-tailed Pearson’s correlation analysis ( B ), and log-rank test ( C ). Source data are provided as a Source Data file.
    Cd8 T Cells Depletion, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cd8 t cells depletion/product/Selleck Chemicals
    Average 95 stars, based on 1 article reviews
    cd8 t cells depletion - by Bioz Stars, 2026-04
    95/100 stars
      Buy from Supplier

    97
    Bio X Cell anti cd8 t cell depletion antibody
    A The expression of neutrophils and <t>CD8</t> + T cells in low- and high-glycolysis clusters, divided by ssGSEA score of glycolysis-related genes, in TCGA and CPTAC PAAD database. Data are presented as box plots showing the median (center line), the first and third quartiles (box bounds), and the whiskers extend to 1.5 times the interquartile range from the box. B The correlation of glycolysis level and neutrophils or CD8 + T cells expression in TCGA ( n = 179 patients) and CPTAC ( n = 140 patients) PAAD database. C Kaplan–Meier plots representing survival probabilities in TCGA-PAAD patients according to the relative level of glycolysis-related or neutrophil-related gene expression. D The diagram illustrating the targets of 2DG and shRNA in the glycolysis process. E CyTOF analysis of tumor-infiltrating immunocytes in subcutaneous tumor models with or without 2DG treatment: tSNE plots showing 12 meta-clusters based on the expression of 41 markers for the immunocytes. F Bar chart of the frequencies of the immune cell subsets in two experimental groups. G A schematic diagram showing the orthotopic PDAC model ( n = 6 mice per group in one experiment) with or without 2DG treatment. H , I Image and weights of the orthotopic tumors in the experimental groups from ( G ) at the end of the experiments. ( n = 6 mice per group). ( J – M ) Tumor-infiltrating neutrophils, CD8 + T cells, GZMB + CD8 + T cells, and PD-1 + CD8 + T cells isolated from the orthotopic tumors were analyzed using flow cytometry: representative graphs of flow cytometry (left panel) and statistical analysis of the cell ratio (right panel) ( n = 6 mice per group). N A schematic diagram showing the orthotopic tumor model in C57BL/6 J mice ( n = 6 mice per group in one experiment) treated with or without anti-Ly6G/anti-CD8 antibody. O , P Image and weights of the orthotopic tumors in the experimental groups from ( N ) at the end of the experiments ( n = 6 mice per group). Q – S Tumor-infiltrating neutrophils, CD8 + T cells, and GZMB + CD8 + T cells isolated from the orthotopic tumors were analyzed using flow cytometry: Representative graphs of flow cytometry (left panel) and statistical analysis of the cell ratio (right panel) ( n = 6 mice per group). T , U Representative luminescence images of the mouse model in ( N ) and statistical analysis of the total flux ( n = 6 mice per group). Data represent mean ± SEM. Statistical analysis was conducted using the two-tailed unpaired Student’s t test ( A, I–M, P–S, and U ), two-tailed Pearson’s correlation analysis ( B ), and log-rank test ( C ). Source data are provided as a Source Data file.
    Anti Cd8 T Cell Depletion Antibody, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti cd8 t cell depletion antibody/product/Bio X Cell
    Average 97 stars, based on 1 article reviews
    anti cd8 t cell depletion antibody - by Bioz Stars, 2026-04
    97/100 stars
      Buy from Supplier

    97
    Bio X Cell cd8 t cell depletion
    (A) Flow cytometry analysis of melanoma antigen panel for MHC-I, MHC-II and PD-L1 in control, responder, and treatment escape groups. Tumor cells were normalized to SOX10 + cells, n=3/group. (B) Immunohistochemistry (IHC) staining and quantification of MHC-I and PD-L1 expression in control, responder, and treatment escape groups, n=3/group. H-score was used to access MHC-I expression and the percentage of positive cells for PD-L1. (C) Flow cytometry analysis of T cell panel (number of infiltrated CD4 + and <t>CD8</t> + T cells, activated CD4 + /CD69 + and CD8 + /CD69 + T cells, and memory CD44 + /CD62L − /CD4 + and CD44 + /CD62L − /CD8 + T cells) of control, responder, and treatment escape groups. Cells were normalized to the total number of live cells. (D) Flow cytometry analysis of Foxp3 + CD4 + T cells (Tregs) in control, responder, and treatment escape groups. Tregs were normalized to the total number of CD4 + cells. (E) Immunohistochemistry staining and quantification of CD8, CD69 and PD-1 expression in control, responder, and treatment escape groups. n=3/group. H-score was used to access CD8 and CD69 expressions and the percentage of positive cells for PD1, according to the best fit suggested by the software. (F) Flow cytometry analysis of exhaustion markers (PD-1, TIM-3, LAG-3 and CTLA-4) in control, responder, and treatment escape groups. T cells were normalized to the total number of live cells. Scale bar = 200 μm (G) Multiplex immunofluorescence (IF) staining of control, responder, and treatment escape tumors for DAPI, CD4, CD8, CD11b, CD11c, Ly6G, Ly6C, CD34 and SOX10 expression (H) Scoring of the multiplex IF images of the whole slides. (I) Degrees of clustering of CD4 + or CD8 + T cells versus M-MDSCs (CD11b + Ly6C + Ly6G − ) and PMN-MDSCs (CD11b + Ly6C − Ly6G + ) of control, responder, and treatment escape groups, n=3/group. Cells were normalized by the number of total cells. The graphs are represented as average ± SEM. One-way ANOVA was performed followed by Tukey’s multiple comparisons test: *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001. ns: non-significant; C: control (not treated cells); R: responder; TE: treatment escape.
    Cd8 T Cell Depletion, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cd8 t cell depletion/product/Bio X Cell
    Average 97 stars, based on 1 article reviews
    cd8 t cell depletion - by Bioz Stars, 2026-04
    97/100 stars
      Buy from Supplier

    95
    Selleck Chemicals cd8 t cell depletion anti mouse cd8 monoclonal antibody
    Fig. 5. Knockout of Acod1 in macrophages further enhance the activation of tumor immune microenvironment by radiotherapy (A) Gating strategy for detection of NK, CD4+ and <t>CD8+</t> T cells by flow cytometry. (B–G) Flow cytometry analysis of CD45+ immune cells (B), CD3+ (C), CD4+ (D), CD8+ (E) T cells, the ratio of CD4+/CD8+ T cells (F), and NK cells (G) in the TME of LLC subcutaneous tumor model in mice treated with radiation (8 Gy x 3) in Acod1f/f Lyz2cre− (HO−) and Acod1f/f Lyz2cre+ (HO+) mice (n = 6). (H) Representative immunofluorescence staining of CD8 (green) in the TME at the end of experiment in Acod1f/f Lyz2cre−(HO−) and Acod1f/f Lyz2cre+ (HO+) mice. (I–J) Flow cytometry analysis of CD107a+ (I), and IFN-γ+ CD8+ T cells (J) in the TME of LLC subcutaneous tumor model described above (n = 6). *p < 0.05; **p < 0.01; ***p < 0.001; ns, not statistically significant.
    Cd8 T Cell Depletion Anti Mouse Cd8 Monoclonal Antibody, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cd8 t cell depletion anti mouse cd8 monoclonal antibody/product/Selleck Chemicals
    Average 95 stars, based on 1 article reviews
    cd8 t cell depletion anti mouse cd8 monoclonal antibody - by Bioz Stars, 2026-04
    95/100 stars
      Buy from Supplier

    95
    Selleck Chemicals cd8 t cell depletion
    Fig. 5. Knockout of Acod1 in macrophages further enhance the activation of tumor immune microenvironment by radiotherapy (A) Gating strategy for detection of NK, CD4+ and <t>CD8+</t> T cells by flow cytometry. (B–G) Flow cytometry analysis of CD45+ immune cells (B), CD3+ (C), CD4+ (D), CD8+ (E) T cells, the ratio of CD4+/CD8+ T cells (F), and NK cells (G) in the TME of LLC subcutaneous tumor model in mice treated with radiation (8 Gy x 3) in Acod1f/f Lyz2cre− (HO−) and Acod1f/f Lyz2cre+ (HO+) mice (n = 6). (H) Representative immunofluorescence staining of CD8 (green) in the TME at the end of experiment in Acod1f/f Lyz2cre−(HO−) and Acod1f/f Lyz2cre+ (HO+) mice. (I–J) Flow cytometry analysis of CD107a+ (I), and IFN-γ+ CD8+ T cells (J) in the TME of LLC subcutaneous tumor model described above (n = 6). *p < 0.05; **p < 0.01; ***p < 0.001; ns, not statistically significant.
    Cd8 T Cell Depletion, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cd8 t cell depletion/product/Selleck Chemicals
    Average 95 stars, based on 1 article reviews
    cd8 t cell depletion - by Bioz Stars, 2026-04
    95/100 stars
      Buy from Supplier

    Image Search Results


    A The expression of neutrophils and CD8 + T cells in low- and high-glycolysis clusters, divided by ssGSEA score of glycolysis-related genes, in TCGA and CPTAC PAAD database. Data are presented as box plots showing the median (center line), the first and third quartiles (box bounds), and the whiskers extend to 1.5 times the interquartile range from the box. B The correlation of glycolysis level and neutrophils or CD8 + T cells expression in TCGA ( n = 179 patients) and CPTAC ( n = 140 patients) PAAD database. C Kaplan–Meier plots representing survival probabilities in TCGA-PAAD patients according to the relative level of glycolysis-related or neutrophil-related gene expression. D The diagram illustrating the targets of 2DG and shRNA in the glycolysis process. E CyTOF analysis of tumor-infiltrating immunocytes in subcutaneous tumor models with or without 2DG treatment: tSNE plots showing 12 meta-clusters based on the expression of 41 markers for the immunocytes. F Bar chart of the frequencies of the immune cell subsets in two experimental groups. G A schematic diagram showing the orthotopic PDAC model ( n = 6 mice per group in one experiment) with or without 2DG treatment. H , I Image and weights of the orthotopic tumors in the experimental groups from ( G ) at the end of the experiments. ( n = 6 mice per group). ( J – M ) Tumor-infiltrating neutrophils, CD8 + T cells, GZMB + CD8 + T cells, and PD-1 + CD8 + T cells isolated from the orthotopic tumors were analyzed using flow cytometry: representative graphs of flow cytometry (left panel) and statistical analysis of the cell ratio (right panel) ( n = 6 mice per group). N A schematic diagram showing the orthotopic tumor model in C57BL/6 J mice ( n = 6 mice per group in one experiment) treated with or without anti-Ly6G/anti-CD8 antibody. O , P Image and weights of the orthotopic tumors in the experimental groups from ( N ) at the end of the experiments ( n = 6 mice per group). Q – S Tumor-infiltrating neutrophils, CD8 + T cells, and GZMB + CD8 + T cells isolated from the orthotopic tumors were analyzed using flow cytometry: Representative graphs of flow cytometry (left panel) and statistical analysis of the cell ratio (right panel) ( n = 6 mice per group). T , U Representative luminescence images of the mouse model in ( N ) and statistical analysis of the total flux ( n = 6 mice per group). Data represent mean ± SEM. Statistical analysis was conducted using the two-tailed unpaired Student’s t test ( A, I–M, P–S, and U ), two-tailed Pearson’s correlation analysis ( B ), and log-rank test ( C ). Source data are provided as a Source Data file.

    Journal: Nature Communications

    Article Title: Histone lactylation increases CXCL1 expression for neutrophil infiltration and immune escape in pancreatic cancer

    doi: 10.1038/s41467-026-69311-5

    Figure Lengend Snippet: A The expression of neutrophils and CD8 + T cells in low- and high-glycolysis clusters, divided by ssGSEA score of glycolysis-related genes, in TCGA and CPTAC PAAD database. Data are presented as box plots showing the median (center line), the first and third quartiles (box bounds), and the whiskers extend to 1.5 times the interquartile range from the box. B The correlation of glycolysis level and neutrophils or CD8 + T cells expression in TCGA ( n = 179 patients) and CPTAC ( n = 140 patients) PAAD database. C Kaplan–Meier plots representing survival probabilities in TCGA-PAAD patients according to the relative level of glycolysis-related or neutrophil-related gene expression. D The diagram illustrating the targets of 2DG and shRNA in the glycolysis process. E CyTOF analysis of tumor-infiltrating immunocytes in subcutaneous tumor models with or without 2DG treatment: tSNE plots showing 12 meta-clusters based on the expression of 41 markers for the immunocytes. F Bar chart of the frequencies of the immune cell subsets in two experimental groups. G A schematic diagram showing the orthotopic PDAC model ( n = 6 mice per group in one experiment) with or without 2DG treatment. H , I Image and weights of the orthotopic tumors in the experimental groups from ( G ) at the end of the experiments. ( n = 6 mice per group). ( J – M ) Tumor-infiltrating neutrophils, CD8 + T cells, GZMB + CD8 + T cells, and PD-1 + CD8 + T cells isolated from the orthotopic tumors were analyzed using flow cytometry: representative graphs of flow cytometry (left panel) and statistical analysis of the cell ratio (right panel) ( n = 6 mice per group). N A schematic diagram showing the orthotopic tumor model in C57BL/6 J mice ( n = 6 mice per group in one experiment) treated with or without anti-Ly6G/anti-CD8 antibody. O , P Image and weights of the orthotopic tumors in the experimental groups from ( N ) at the end of the experiments ( n = 6 mice per group). Q – S Tumor-infiltrating neutrophils, CD8 + T cells, and GZMB + CD8 + T cells isolated from the orthotopic tumors were analyzed using flow cytometry: Representative graphs of flow cytometry (left panel) and statistical analysis of the cell ratio (right panel) ( n = 6 mice per group). T , U Representative luminescence images of the mouse model in ( N ) and statistical analysis of the total flux ( n = 6 mice per group). Data represent mean ± SEM. Statistical analysis was conducted using the two-tailed unpaired Student’s t test ( A, I–M, P–S, and U ), two-tailed Pearson’s correlation analysis ( B ), and log-rank test ( C ). Source data are provided as a Source Data file.

    Article Snippet: After 11 consecutive days of antibody administration, the mice were euthanized, the peripheral blood was harvested for flow cytometry analysis to assess the efficiency of neutrophil depletion; (3) For CD8 + T cells depletion, mice received an intraperitoneal injection of anti-IgG2a or anti-CD8 antibody (Selleck, #A2102) treatment (0.2 mg/mouse, i.p.) 2 days before implantation.

    Techniques: Expressing, Gene Expression, shRNA, Isolation, Flow Cytometry, Two Tailed Test

    A The flowchart illustrates that RNA sequencing was conducted using two PDAC cell lines with or without 2DG treatment. Subsequently, the intersection of detected genes within the chemokine family in both cell lines is identified, and a heatmap is generated to display the log 2 fold change (2DG versus vehicle) of these genes. B , C Relative mRNA levels of Cxcl1 in PDAC cell lines following glycolysis inhibition, either by using 2DG or silencing LDH, were analyzed by qRT-PCR ( n = 3 independent experiments). D , E Relative protein levels of CXCL1 in PDAC cell lines following glycolysis inhibition, either by using 2DG or silencing LDH, were determined using ELISA assay ( n = 3 independent experiments). F Representative IHC images of subcutaneous tumors ( n = 6 mice for 2DG treatment, n = 5 mice for shLDH/shNTC groups) stained by CXCL1 antibody (scale bars = 100 μm). G Relative serum CXCL1 levels in mice treated with or without 2DG were measured by ELISA ( n = 6 mice per group). H Relative serum CXCL1 levels in healthy donors and PDAC patients were measured by ELISA (22 healthy samples and 27 PDAC samples). I Schematic diagram showing the in vitro migration assay: human/mouse neutrophils were co-incubated with the culture medium supernatant from PDAC cells treated with 2DG or LDH-knockdown. J Neutrophils were co-cultured with CD8 + T cells in different proportions, and the proliferation of CD8 + T cells was detected with the CFSE assay ( n = 6 biologically independent samples). K The migratory activity of neutrophils co-incubated with the culture medium supernatant from PDAC cells treated with shLDH and recombinant CXCL1 was analyzed by counting the penetrated cell numbers ( n = 3 biologically independent samples). L The neutrophils were treated with SX-682 or Navarixin for 1.5 h in advance, and the migratory activity of neutrophils co-incubated with the culture medium supernatant from PDAC cell lines treated with shLDH was analyzed by counting the penetrated cell numbers ( n = 3 biologically independent samples). M Representative luminescence images of the orthotopic tumor in mice and statistical analysis of MFI ( n = 5 mice per group). N Tumor-infiltrating neutrophils isolated from the orthotopic tumors were analyzed using flow cytometry ( n = 5 mice per group). Data represent mean ± SEM. Statistical analysis was conducted using the two-tailed unpaired Student’s t test. Source data are provided as a Source Data file.

    Journal: Nature Communications

    Article Title: Histone lactylation increases CXCL1 expression for neutrophil infiltration and immune escape in pancreatic cancer

    doi: 10.1038/s41467-026-69311-5

    Figure Lengend Snippet: A The flowchart illustrates that RNA sequencing was conducted using two PDAC cell lines with or without 2DG treatment. Subsequently, the intersection of detected genes within the chemokine family in both cell lines is identified, and a heatmap is generated to display the log 2 fold change (2DG versus vehicle) of these genes. B , C Relative mRNA levels of Cxcl1 in PDAC cell lines following glycolysis inhibition, either by using 2DG or silencing LDH, were analyzed by qRT-PCR ( n = 3 independent experiments). D , E Relative protein levels of CXCL1 in PDAC cell lines following glycolysis inhibition, either by using 2DG or silencing LDH, were determined using ELISA assay ( n = 3 independent experiments). F Representative IHC images of subcutaneous tumors ( n = 6 mice for 2DG treatment, n = 5 mice for shLDH/shNTC groups) stained by CXCL1 antibody (scale bars = 100 μm). G Relative serum CXCL1 levels in mice treated with or without 2DG were measured by ELISA ( n = 6 mice per group). H Relative serum CXCL1 levels in healthy donors and PDAC patients were measured by ELISA (22 healthy samples and 27 PDAC samples). I Schematic diagram showing the in vitro migration assay: human/mouse neutrophils were co-incubated with the culture medium supernatant from PDAC cells treated with 2DG or LDH-knockdown. J Neutrophils were co-cultured with CD8 + T cells in different proportions, and the proliferation of CD8 + T cells was detected with the CFSE assay ( n = 6 biologically independent samples). K The migratory activity of neutrophils co-incubated with the culture medium supernatant from PDAC cells treated with shLDH and recombinant CXCL1 was analyzed by counting the penetrated cell numbers ( n = 3 biologically independent samples). L The neutrophils were treated with SX-682 or Navarixin for 1.5 h in advance, and the migratory activity of neutrophils co-incubated with the culture medium supernatant from PDAC cell lines treated with shLDH was analyzed by counting the penetrated cell numbers ( n = 3 biologically independent samples). M Representative luminescence images of the orthotopic tumor in mice and statistical analysis of MFI ( n = 5 mice per group). N Tumor-infiltrating neutrophils isolated from the orthotopic tumors were analyzed using flow cytometry ( n = 5 mice per group). Data represent mean ± SEM. Statistical analysis was conducted using the two-tailed unpaired Student’s t test. Source data are provided as a Source Data file.

    Article Snippet: After 11 consecutive days of antibody administration, the mice were euthanized, the peripheral blood was harvested for flow cytometry analysis to assess the efficiency of neutrophil depletion; (3) For CD8 + T cells depletion, mice received an intraperitoneal injection of anti-IgG2a or anti-CD8 antibody (Selleck, #A2102) treatment (0.2 mg/mouse, i.p.) 2 days before implantation.

    Techniques: RNA Sequencing, Generated, Inhibition, Quantitative RT-PCR, Enzyme-linked Immunosorbent Assay, Staining, In Vitro, Migration, Incubation, Knockdown, Cell Culture, CFSE Assay, Activity Assay, Recombinant, Isolation, Flow Cytometry, Two Tailed Test

    A Molecular docking simulated the binding affinities of PCAF for acetyl-CoA and lactyl-CoA. B Co-IP was performed to confirm the interaction between H3K18la and PCAF in PANC1 and KPC cells. PCAF and H3K18la were detected on the same gel. C, D Western blot analysis demonstrates the level of H3K18la in PDAC cells with or without the treatment of PCAF inhibitors (bromosporine or Embelin). Histone H3 and H3K18la blots are from parallel-processed separate gels (size conflict) with samples from the same experiment. E Western blot analysis demonstrates the level of H3K18la in PDAC cells following the knockdown of Pcaf . Histone H3, PCAF, β-actin and H3K18la blots are from parallel-processed separate gels with samples from the same experiment. F Western blots of in vitro histone acetylation or lactylation assay, the samples as indicated. Blots are from parallel-processed separate gels with samples from the same experiment. G , H Relative Cxcl1 RNA and protein levels with the vehicle or bromosporine treatment were analyzed by qRT-PCR and ELISA ( n = 3 independent experiments), respectively. I Relative Cxcl1 RNA levels after Pcaf knockdown were analyzed by qRT-PCR ( n = 3 independent experiments). J A schematic diagram showing the orthotopic tumor construction in C57BL/6 J mice ( n = 5 mice per group in one experiment, 2 × 10 6 KPC-luc cells per mouse) with or without bromosporine treatment. K , L Image and weights of the orthotopic tumors in the experimental groups from ( J ) at the end of the experiments ( n = 5 mice per group). M Lactylation levels of H3K18 and PanK in orthotopic tumors with or without bromosporine treatment were detected by western blot ( n = 4 biologically independent samples per group). Histone H3, H3K18la, and PanKla blots are from parallel-processed separate gels (size conflict) with samples from the same experiment. N Serum CXCL1 levels in mice with or without bromosporine treatment were measured by ELISA ( n = 5 mice per group). O – R Tumor-infiltrating neutrophils, CD8 + T cells, GZMB + CD8 + T cells, and PD-1 + CD8 + T cells isolated from the orthotopic tumors were analyzed using flow cytometry. Representative graphs of flow cytometry (left panel) and statistical analysis of the cell ratio (right panel) ( n = 5 mice per group). S The migratory abilities of neutrophils co-incubated with the culture medium supernatant from shNTC/ Pcaf PDAC cells treated with recombinant CXCL1 were analyzed by counting the penetrated cell numbers ( n = 3 biologically independent samples). T Representative IHC images stained by CXCL1 or H3K18la antibody (scale bar = 100 μm, left panel), correlation analysis of H-scores of CXCL1 and H3K18la in PDAC samples ( n = 21 patients, right panel). Data represent mean ± SEM. Statistical analysis was conducted using the two-tailed unpaired Student’s t test ( G – I , L , and N – S ) and two-tailed Pearson’s correlation analysis ( T ). Unless otherwise indicated, all western blots had three independent experimental repetitions with consistent results. Source data are provided as a Source Data file.

    Journal: Nature Communications

    Article Title: Histone lactylation increases CXCL1 expression for neutrophil infiltration and immune escape in pancreatic cancer

    doi: 10.1038/s41467-026-69311-5

    Figure Lengend Snippet: A Molecular docking simulated the binding affinities of PCAF for acetyl-CoA and lactyl-CoA. B Co-IP was performed to confirm the interaction between H3K18la and PCAF in PANC1 and KPC cells. PCAF and H3K18la were detected on the same gel. C, D Western blot analysis demonstrates the level of H3K18la in PDAC cells with or without the treatment of PCAF inhibitors (bromosporine or Embelin). Histone H3 and H3K18la blots are from parallel-processed separate gels (size conflict) with samples from the same experiment. E Western blot analysis demonstrates the level of H3K18la in PDAC cells following the knockdown of Pcaf . Histone H3, PCAF, β-actin and H3K18la blots are from parallel-processed separate gels with samples from the same experiment. F Western blots of in vitro histone acetylation or lactylation assay, the samples as indicated. Blots are from parallel-processed separate gels with samples from the same experiment. G , H Relative Cxcl1 RNA and protein levels with the vehicle or bromosporine treatment were analyzed by qRT-PCR and ELISA ( n = 3 independent experiments), respectively. I Relative Cxcl1 RNA levels after Pcaf knockdown were analyzed by qRT-PCR ( n = 3 independent experiments). J A schematic diagram showing the orthotopic tumor construction in C57BL/6 J mice ( n = 5 mice per group in one experiment, 2 × 10 6 KPC-luc cells per mouse) with or without bromosporine treatment. K , L Image and weights of the orthotopic tumors in the experimental groups from ( J ) at the end of the experiments ( n = 5 mice per group). M Lactylation levels of H3K18 and PanK in orthotopic tumors with or without bromosporine treatment were detected by western blot ( n = 4 biologically independent samples per group). Histone H3, H3K18la, and PanKla blots are from parallel-processed separate gels (size conflict) with samples from the same experiment. N Serum CXCL1 levels in mice with or without bromosporine treatment were measured by ELISA ( n = 5 mice per group). O – R Tumor-infiltrating neutrophils, CD8 + T cells, GZMB + CD8 + T cells, and PD-1 + CD8 + T cells isolated from the orthotopic tumors were analyzed using flow cytometry. Representative graphs of flow cytometry (left panel) and statistical analysis of the cell ratio (right panel) ( n = 5 mice per group). S The migratory abilities of neutrophils co-incubated with the culture medium supernatant from shNTC/ Pcaf PDAC cells treated with recombinant CXCL1 were analyzed by counting the penetrated cell numbers ( n = 3 biologically independent samples). T Representative IHC images stained by CXCL1 or H3K18la antibody (scale bar = 100 μm, left panel), correlation analysis of H-scores of CXCL1 and H3K18la in PDAC samples ( n = 21 patients, right panel). Data represent mean ± SEM. Statistical analysis was conducted using the two-tailed unpaired Student’s t test ( G – I , L , and N – S ) and two-tailed Pearson’s correlation analysis ( T ). Unless otherwise indicated, all western blots had three independent experimental repetitions with consistent results. Source data are provided as a Source Data file.

    Article Snippet: After 11 consecutive days of antibody administration, the mice were euthanized, the peripheral blood was harvested for flow cytometry analysis to assess the efficiency of neutrophil depletion; (3) For CD8 + T cells depletion, mice received an intraperitoneal injection of anti-IgG2a or anti-CD8 antibody (Selleck, #A2102) treatment (0.2 mg/mouse, i.p.) 2 days before implantation.

    Techniques: Binding Assay, Co-Immunoprecipitation Assay, Western Blot, Knockdown, In Vitro, Quantitative RT-PCR, Enzyme-linked Immunosorbent Assay, Isolation, Flow Cytometry, Incubation, Recombinant, Staining, Two Tailed Test

    A A schematic diagram showing the subcutaneous tumor model ( n = 6 mice per group in one experiment, 6 × 10 6 PANC02 cells per mouse) treated with bromosporine and anti-PD-1 antibody. B. The tumor volume growth curves of subcutaneous tumors from ( A ). C , D Image and weights of the subcutaneous tumors at the end point of experiments ( n = 6 mice per group). E The statistical analysis of the cell ratio of tumor-infiltrating neutrophils and CD8 + T cells isolated from subcutaneous tumors ( n = 3 mice per group). F Western blot analysis demonstrates H3K18la levels in the subcutaneous tumors ( n = 3 biologically independent samples per group) from ( A ). Histone H3 and H3K18la blots are from parallel-processed separate gels (size conflict) with samples from the same experiment. G Relative serum CXCL1 levels in mice treated with or without bromosporine/anti-PD-1 antibody were measured by ELISA ( n = 6 mice per group). H A schematic diagram showing the combinational treatment schedule for the orthotopic KPC-luc tumor model ( n = 21 mice per group in one experiment, 2 × 10 6 KPC-luc cells per mouse). I , J Image and weights of the orthotopic tumors at the end point of experiments ( n = 6 mice per group). K – N Tumor-infiltrating neutrophils, CD8 + T cells, GZMB + CD8 + T cells, and PD-1 + CD8 + T cells were analyzed using flow cytometry. Representative graphs of flow cytometry (left panel) and statistical analysis of the cell ratio (right panel) ( n = 6 mice per group). O Western blot analysis showing the H3K18la levels in the orthotopic tumors ( n = 3 biologically independent samples per group) from ( H ). Histone H3 and H3K18la blots are from parallel-processed separate gels (size conflict) with samples from the same experiment. P Representative luminescence images and Quantification of radiance intensity of the mouse model in ( H ). Q Survival probability of mice with orthotopically transplanted PDAC ( n = 15 mice per group). R A working model displaying the signaling pathway through which the aerobic glycolysis-mediated Lactate-PCAF-H3K18la-CXCL1 axis modulates the tumor microenvironment in pancreatic cancer, and the scientific basis for the development of a novel therapeutic strategy for PDAC. Data represent mean ± SEM. Statistical analysis was conducted using the two-tailed unpaired Student’s t test ( B , D , E , G , J – N , P ) and the log-rank test ( Q ). Source data are provided as a Source Data file.

    Journal: Nature Communications

    Article Title: Histone lactylation increases CXCL1 expression for neutrophil infiltration and immune escape in pancreatic cancer

    doi: 10.1038/s41467-026-69311-5

    Figure Lengend Snippet: A A schematic diagram showing the subcutaneous tumor model ( n = 6 mice per group in one experiment, 6 × 10 6 PANC02 cells per mouse) treated with bromosporine and anti-PD-1 antibody. B. The tumor volume growth curves of subcutaneous tumors from ( A ). C , D Image and weights of the subcutaneous tumors at the end point of experiments ( n = 6 mice per group). E The statistical analysis of the cell ratio of tumor-infiltrating neutrophils and CD8 + T cells isolated from subcutaneous tumors ( n = 3 mice per group). F Western blot analysis demonstrates H3K18la levels in the subcutaneous tumors ( n = 3 biologically independent samples per group) from ( A ). Histone H3 and H3K18la blots are from parallel-processed separate gels (size conflict) with samples from the same experiment. G Relative serum CXCL1 levels in mice treated with or without bromosporine/anti-PD-1 antibody were measured by ELISA ( n = 6 mice per group). H A schematic diagram showing the combinational treatment schedule for the orthotopic KPC-luc tumor model ( n = 21 mice per group in one experiment, 2 × 10 6 KPC-luc cells per mouse). I , J Image and weights of the orthotopic tumors at the end point of experiments ( n = 6 mice per group). K – N Tumor-infiltrating neutrophils, CD8 + T cells, GZMB + CD8 + T cells, and PD-1 + CD8 + T cells were analyzed using flow cytometry. Representative graphs of flow cytometry (left panel) and statistical analysis of the cell ratio (right panel) ( n = 6 mice per group). O Western blot analysis showing the H3K18la levels in the orthotopic tumors ( n = 3 biologically independent samples per group) from ( H ). Histone H3 and H3K18la blots are from parallel-processed separate gels (size conflict) with samples from the same experiment. P Representative luminescence images and Quantification of radiance intensity of the mouse model in ( H ). Q Survival probability of mice with orthotopically transplanted PDAC ( n = 15 mice per group). R A working model displaying the signaling pathway through which the aerobic glycolysis-mediated Lactate-PCAF-H3K18la-CXCL1 axis modulates the tumor microenvironment in pancreatic cancer, and the scientific basis for the development of a novel therapeutic strategy for PDAC. Data represent mean ± SEM. Statistical analysis was conducted using the two-tailed unpaired Student’s t test ( B , D , E , G , J – N , P ) and the log-rank test ( Q ). Source data are provided as a Source Data file.

    Article Snippet: After 11 consecutive days of antibody administration, the mice were euthanized, the peripheral blood was harvested for flow cytometry analysis to assess the efficiency of neutrophil depletion; (3) For CD8 + T cells depletion, mice received an intraperitoneal injection of anti-IgG2a or anti-CD8 antibody (Selleck, #A2102) treatment (0.2 mg/mouse, i.p.) 2 days before implantation.

    Techniques: Isolation, Western Blot, Enzyme-linked Immunosorbent Assay, Flow Cytometry, Two Tailed Test

    (A) Flow cytometry analysis of melanoma antigen panel for MHC-I, MHC-II and PD-L1 in control, responder, and treatment escape groups. Tumor cells were normalized to SOX10 + cells, n=3/group. (B) Immunohistochemistry (IHC) staining and quantification of MHC-I and PD-L1 expression in control, responder, and treatment escape groups, n=3/group. H-score was used to access MHC-I expression and the percentage of positive cells for PD-L1. (C) Flow cytometry analysis of T cell panel (number of infiltrated CD4 + and CD8 + T cells, activated CD4 + /CD69 + and CD8 + /CD69 + T cells, and memory CD44 + /CD62L − /CD4 + and CD44 + /CD62L − /CD8 + T cells) of control, responder, and treatment escape groups. Cells were normalized to the total number of live cells. (D) Flow cytometry analysis of Foxp3 + CD4 + T cells (Tregs) in control, responder, and treatment escape groups. Tregs were normalized to the total number of CD4 + cells. (E) Immunohistochemistry staining and quantification of CD8, CD69 and PD-1 expression in control, responder, and treatment escape groups. n=3/group. H-score was used to access CD8 and CD69 expressions and the percentage of positive cells for PD1, according to the best fit suggested by the software. (F) Flow cytometry analysis of exhaustion markers (PD-1, TIM-3, LAG-3 and CTLA-4) in control, responder, and treatment escape groups. T cells were normalized to the total number of live cells. Scale bar = 200 μm (G) Multiplex immunofluorescence (IF) staining of control, responder, and treatment escape tumors for DAPI, CD4, CD8, CD11b, CD11c, Ly6G, Ly6C, CD34 and SOX10 expression (H) Scoring of the multiplex IF images of the whole slides. (I) Degrees of clustering of CD4 + or CD8 + T cells versus M-MDSCs (CD11b + Ly6C + Ly6G − ) and PMN-MDSCs (CD11b + Ly6C − Ly6G + ) of control, responder, and treatment escape groups, n=3/group. Cells were normalized by the number of total cells. The graphs are represented as average ± SEM. One-way ANOVA was performed followed by Tukey’s multiple comparisons test: *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001. ns: non-significant; C: control (not treated cells); R: responder; TE: treatment escape.

    Journal: Cancer immunology research

    Article Title: RAS(ON) multi-selective inhibition drives antitumor immunity in preclinical models of NRAS -mutant melanoma

    doi: 10.1158/2326-6066.CIR-25-0744

    Figure Lengend Snippet: (A) Flow cytometry analysis of melanoma antigen panel for MHC-I, MHC-II and PD-L1 in control, responder, and treatment escape groups. Tumor cells were normalized to SOX10 + cells, n=3/group. (B) Immunohistochemistry (IHC) staining and quantification of MHC-I and PD-L1 expression in control, responder, and treatment escape groups, n=3/group. H-score was used to access MHC-I expression and the percentage of positive cells for PD-L1. (C) Flow cytometry analysis of T cell panel (number of infiltrated CD4 + and CD8 + T cells, activated CD4 + /CD69 + and CD8 + /CD69 + T cells, and memory CD44 + /CD62L − /CD4 + and CD44 + /CD62L − /CD8 + T cells) of control, responder, and treatment escape groups. Cells were normalized to the total number of live cells. (D) Flow cytometry analysis of Foxp3 + CD4 + T cells (Tregs) in control, responder, and treatment escape groups. Tregs were normalized to the total number of CD4 + cells. (E) Immunohistochemistry staining and quantification of CD8, CD69 and PD-1 expression in control, responder, and treatment escape groups. n=3/group. H-score was used to access CD8 and CD69 expressions and the percentage of positive cells for PD1, according to the best fit suggested by the software. (F) Flow cytometry analysis of exhaustion markers (PD-1, TIM-3, LAG-3 and CTLA-4) in control, responder, and treatment escape groups. T cells were normalized to the total number of live cells. Scale bar = 200 μm (G) Multiplex immunofluorescence (IF) staining of control, responder, and treatment escape tumors for DAPI, CD4, CD8, CD11b, CD11c, Ly6G, Ly6C, CD34 and SOX10 expression (H) Scoring of the multiplex IF images of the whole slides. (I) Degrees of clustering of CD4 + or CD8 + T cells versus M-MDSCs (CD11b + Ly6C + Ly6G − ) and PMN-MDSCs (CD11b + Ly6C − Ly6G + ) of control, responder, and treatment escape groups, n=3/group. Cells were normalized by the number of total cells. The graphs are represented as average ± SEM. One-way ANOVA was performed followed by Tukey’s multiple comparisons test: *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001. ns: non-significant; C: control (not treated cells); R: responder; TE: treatment escape.

    Article Snippet: For CD4 + and CD8 + T-cell depletion, specific antibodies (anti-CD4, clone YTS191; cat. #BE0003–1; BioXCell, RRID:AB_1107636 and anti-CD8a, clone YTS169.4, cat. #BE0117, BioXCell, RRID:AB_10950145) were used.

    Techniques: Flow Cytometry, Control, Immunohistochemistry, Expressing, Staining, Software, Multiplex Assay, Immunofluorescence

    (A-B) Tumor growth and survival curves following pre-treatment with IgG control (n=5) or anti-CD4 + anti-CD8a +/− RMC-7977 (all n=15). Vehicle or RMC-7977 treatment was initiated when tumors reached around 100mm 3 . For T cell depletion, mice were treated 3 days before the injection of the tumor with the Anti-CD4 and Anti-CD8a antibodies (1µg/µL, I.P.) and then every 4 days thereafter. The T cell depleted mice were treated with Anti-CD4 and Anti-CD8a antibodies (1µg/µL, I.P., every 4 days), Anti-CD4 + Anti-CD8a + RMC-7977 was treated with Anti-CD4 and Anti-CD8a antibodies (1µg/µL, I.P., every 4 days) and RMC-7977 (25 mg/kg, P.O., q.d.); and RMC-7977 group was treated with only RMC-7977 (25 mg/kg, P.O., q.d.) for 7 weeks. Plots correspond to each individual mouse. Dotted lines indicate when treatment started and stopped.

    Journal: Cancer immunology research

    Article Title: RAS(ON) multi-selective inhibition drives antitumor immunity in preclinical models of NRAS -mutant melanoma

    doi: 10.1158/2326-6066.CIR-25-0744

    Figure Lengend Snippet: (A-B) Tumor growth and survival curves following pre-treatment with IgG control (n=5) or anti-CD4 + anti-CD8a +/− RMC-7977 (all n=15). Vehicle or RMC-7977 treatment was initiated when tumors reached around 100mm 3 . For T cell depletion, mice were treated 3 days before the injection of the tumor with the Anti-CD4 and Anti-CD8a antibodies (1µg/µL, I.P.) and then every 4 days thereafter. The T cell depleted mice were treated with Anti-CD4 and Anti-CD8a antibodies (1µg/µL, I.P., every 4 days), Anti-CD4 + Anti-CD8a + RMC-7977 was treated with Anti-CD4 and Anti-CD8a antibodies (1µg/µL, I.P., every 4 days) and RMC-7977 (25 mg/kg, P.O., q.d.); and RMC-7977 group was treated with only RMC-7977 (25 mg/kg, P.O., q.d.) for 7 weeks. Plots correspond to each individual mouse. Dotted lines indicate when treatment started and stopped.

    Article Snippet: For CD4 + and CD8 + T-cell depletion, specific antibodies (anti-CD4, clone YTS191; cat. #BE0003–1; BioXCell, RRID:AB_1107636 and anti-CD8a, clone YTS169.4, cat. #BE0117, BioXCell, RRID:AB_10950145) were used.

    Techniques: Control, Injection

    (A-B) The effects of IgG control, anti-PD-1, RMC-7977 or anti-PD-1+RMC-7977 on the growth of OSUMMER.13 tumors. Treatment was initiated when tumors reached around 100mm 3 . The IgG group was treated with IgG control (2µg/µL, I.P., every 5 days: n=5), the vehicle group was treated with vehicle (P.O., q.d.: n=5), the vehicle + IgG group was treated with IgG control (2µg/µL, I.P., every 5 days: n=5) and vehicle (P.O., q.d.: n=5), total of n=15M for controls, the anti-PD-1 group was treated with Anti-PD-1 (2µg/µL, I.P., every 5 days: n=7), the RMC-7977 group was treated with RMC-7977 (25 mg/kg, P.O., q.d.: n=7), and the RMC-7977 + anti-PD-1 group (n=7) was treated with a combination of RMC-7977 and Anti-PD1 as indicated for 7 weeks. Plots correspond to each individual mouse. (C) Immunohistochemistry and quantification of pERK, Ki67, Melan-A, CD8, CD69, PD-1 and MHC-I of control (vehicle), anti-PD-1, RMC-7977 and RMC-7977 + anti-PD-1 group, n=3/group. H-score was used to access pERK, Ki67 and MHC-I expressions and the percentage of positive cells for melan-A and PD1, according to the best fit suggested by the software. Scale bar = 200 μm (D) Flow cytometry analysis of the T cell panel (number of infiltrated CD4 + and CD8 + T cells, activated CD4 + /CD69 + and CD8 + /CD69 + T cells, and memory CD44 + /CD62L − /CD4 + and CD44 + /CD62L − /CD8 + T cells) of vehicle, anti-PD1, RMC-7977 and the RMC-7977 + anti-PD-1 groups. The graphs are represented as average ± SEM. One-way ANOVA was performed followed by Tukey’s multiple comparisons test: *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001. ns: non-significant. Dotted lines indicate when treatment started, stopped and when rechallenge was carried out.

    Journal: Cancer immunology research

    Article Title: RAS(ON) multi-selective inhibition drives antitumor immunity in preclinical models of NRAS -mutant melanoma

    doi: 10.1158/2326-6066.CIR-25-0744

    Figure Lengend Snippet: (A-B) The effects of IgG control, anti-PD-1, RMC-7977 or anti-PD-1+RMC-7977 on the growth of OSUMMER.13 tumors. Treatment was initiated when tumors reached around 100mm 3 . The IgG group was treated with IgG control (2µg/µL, I.P., every 5 days: n=5), the vehicle group was treated with vehicle (P.O., q.d.: n=5), the vehicle + IgG group was treated with IgG control (2µg/µL, I.P., every 5 days: n=5) and vehicle (P.O., q.d.: n=5), total of n=15M for controls, the anti-PD-1 group was treated with Anti-PD-1 (2µg/µL, I.P., every 5 days: n=7), the RMC-7977 group was treated with RMC-7977 (25 mg/kg, P.O., q.d.: n=7), and the RMC-7977 + anti-PD-1 group (n=7) was treated with a combination of RMC-7977 and Anti-PD1 as indicated for 7 weeks. Plots correspond to each individual mouse. (C) Immunohistochemistry and quantification of pERK, Ki67, Melan-A, CD8, CD69, PD-1 and MHC-I of control (vehicle), anti-PD-1, RMC-7977 and RMC-7977 + anti-PD-1 group, n=3/group. H-score was used to access pERK, Ki67 and MHC-I expressions and the percentage of positive cells for melan-A and PD1, according to the best fit suggested by the software. Scale bar = 200 μm (D) Flow cytometry analysis of the T cell panel (number of infiltrated CD4 + and CD8 + T cells, activated CD4 + /CD69 + and CD8 + /CD69 + T cells, and memory CD44 + /CD62L − /CD4 + and CD44 + /CD62L − /CD8 + T cells) of vehicle, anti-PD1, RMC-7977 and the RMC-7977 + anti-PD-1 groups. The graphs are represented as average ± SEM. One-way ANOVA was performed followed by Tukey’s multiple comparisons test: *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001. ns: non-significant. Dotted lines indicate when treatment started, stopped and when rechallenge was carried out.

    Article Snippet: For CD4 + and CD8 + T-cell depletion, specific antibodies (anti-CD4, clone YTS191; cat. #BE0003–1; BioXCell, RRID:AB_1107636 and anti-CD8a, clone YTS169.4, cat. #BE0117, BioXCell, RRID:AB_10950145) were used.

    Techniques: Control, Immunohistochemistry, Software, Flow Cytometry

    Fig. 5. Knockout of Acod1 in macrophages further enhance the activation of tumor immune microenvironment by radiotherapy (A) Gating strategy for detection of NK, CD4+ and CD8+ T cells by flow cytometry. (B–G) Flow cytometry analysis of CD45+ immune cells (B), CD3+ (C), CD4+ (D), CD8+ (E) T cells, the ratio of CD4+/CD8+ T cells (F), and NK cells (G) in the TME of LLC subcutaneous tumor model in mice treated with radiation (8 Gy x 3) in Acod1f/f Lyz2cre− (HO−) and Acod1f/f Lyz2cre+ (HO+) mice (n = 6). (H) Representative immunofluorescence staining of CD8 (green) in the TME at the end of experiment in Acod1f/f Lyz2cre−(HO−) and Acod1f/f Lyz2cre+ (HO+) mice. (I–J) Flow cytometry analysis of CD107a+ (I), and IFN-γ+ CD8+ T cells (J) in the TME of LLC subcutaneous tumor model described above (n = 6). *p < 0.05; **p < 0.01; ***p < 0.001; ns, not statistically significant.

    Journal: Redox biology

    Article Title: Radiation-induced upregulation of itaconate in macrophages promotes the radioresistance of non-small cell lung cancer by stabilizing NRF2 protein and suppressing immune response.

    doi: 10.1016/j.redox.2025.103711

    Figure Lengend Snippet: Fig. 5. Knockout of Acod1 in macrophages further enhance the activation of tumor immune microenvironment by radiotherapy (A) Gating strategy for detection of NK, CD4+ and CD8+ T cells by flow cytometry. (B–G) Flow cytometry analysis of CD45+ immune cells (B), CD3+ (C), CD4+ (D), CD8+ (E) T cells, the ratio of CD4+/CD8+ T cells (F), and NK cells (G) in the TME of LLC subcutaneous tumor model in mice treated with radiation (8 Gy x 3) in Acod1f/f Lyz2cre− (HO−) and Acod1f/f Lyz2cre+ (HO+) mice (n = 6). (H) Representative immunofluorescence staining of CD8 (green) in the TME at the end of experiment in Acod1f/f Lyz2cre−(HO−) and Acod1f/f Lyz2cre+ (HO+) mice. (I–J) Flow cytometry analysis of CD107a+ (I), and IFN-γ+ CD8+ T cells (J) in the TME of LLC subcutaneous tumor model described above (n = 6). *p < 0.05; **p < 0.01; ***p < 0.001; ns, not statistically significant.

    Article Snippet: CD8+ T cell depletion Anti-mouse CD8 monoclonal antibody (clone 2.43) (#A2102, Selleck, China) was intraperitoneally injected at a dose of 200 μg per mouse, and 150 μg per mouse was injected 3 days later.

    Techniques: Knock-Out, Activation Assay, Flow Cytometry, Immunofluorescence, Staining

    Fig. 6. The antitumor effect of Acod1 knockout in macrophages combined with radiotherapy partially depends on CD8+ T cells (A) CD8+ T cells clearance efficiency in mouse spleen detected by flow cytometry (n = 3). (B) CD8+ T cells clearance efficiency in mouse peripheral blood detected by flow cytometry (n = 3). (C) Tumor growth curves of LLC subcutaneous tumor in Acod1f/f Lyz2cre−(HO−) and Acod1f/f Lyz2cre+ (HO+) mice treated with 8 Gy x 3 radiotherapy and IgG or neutralizing CD8 antibody (α-CD8) (n = 6). (D–E) Tumor weight (D) and tumor images (E) on day 16 after treatment in different groups (n = 6). (F) The schematic diagram depicting that macrophages up-regulate the expression of Acod1 through activating NF-κB pathway after radiotherapy, thereby regulating the radiosensitivity of tumor cells and immune cell infiltration. *p < 0.05; **p < 0.01; ***p < 0.001; ns, not statistically significant.

    Journal: Redox biology

    Article Title: Radiation-induced upregulation of itaconate in macrophages promotes the radioresistance of non-small cell lung cancer by stabilizing NRF2 protein and suppressing immune response.

    doi: 10.1016/j.redox.2025.103711

    Figure Lengend Snippet: Fig. 6. The antitumor effect of Acod1 knockout in macrophages combined with radiotherapy partially depends on CD8+ T cells (A) CD8+ T cells clearance efficiency in mouse spleen detected by flow cytometry (n = 3). (B) CD8+ T cells clearance efficiency in mouse peripheral blood detected by flow cytometry (n = 3). (C) Tumor growth curves of LLC subcutaneous tumor in Acod1f/f Lyz2cre−(HO−) and Acod1f/f Lyz2cre+ (HO+) mice treated with 8 Gy x 3 radiotherapy and IgG or neutralizing CD8 antibody (α-CD8) (n = 6). (D–E) Tumor weight (D) and tumor images (E) on day 16 after treatment in different groups (n = 6). (F) The schematic diagram depicting that macrophages up-regulate the expression of Acod1 through activating NF-κB pathway after radiotherapy, thereby regulating the radiosensitivity of tumor cells and immune cell infiltration. *p < 0.05; **p < 0.01; ***p < 0.001; ns, not statistically significant.

    Article Snippet: CD8+ T cell depletion Anti-mouse CD8 monoclonal antibody (clone 2.43) (#A2102, Selleck, China) was intraperitoneally injected at a dose of 200 μg per mouse, and 150 μg per mouse was injected 3 days later.

    Techniques: Knock-Out, Flow Cytometry, Expressing